From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

BARDA Seeks Single Dose Anthrax Post-Exposure Vaccine

by Global Biodefense Staff
March 9, 2016
Bacillus Anthracis - Anthrax

The Biomedical Advanced Research and Development Authority (BARDA) is conducting research on market availability and capabilities for advanced development and manufacturing of next-generation anthrax vaccines.

The effort supports BARDA’s understanding of the current and future marketplace for planning purposes towards the possible procurement of Post-Exposure Prophylaxis (PEP) vaccines in the event of an anthrax biothreat event.

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillius anthracis, whichcan cause human disease via gastrointestinal, cutaneous, or inhalation routes.  The anthrax vaccine Biothrax® is currently licensed for PEP, however, it requires a three-dose vaccine regimen over 28 days to confer protection.

This three-dose requirement enhances the difficulty in delivery and adherence to the regimen amongst a civilian population in the event of a mass exposure. As such, BARDA is seeking a next-generation vaccine capable of reducing the number of vaccinations needed to confer protection post-exposure.

Characteristics of a new vaccine suitable for a PEP indication include rapid onset of protective immunity in one or two doses and capability for use in conjunction with antibiotics after exposure.

Improvements such as protection against all forms of anthrax, protection in special populations (children, elderly, and the immunocompromised), and elimination of cold chain storage would be considered additional enhancements for an ideal candidate.

Further details are available via Solicitation Number: BARDA-2016-Next-Generation-Anthrax-Vaccine-(01A). The RFI deadline is March 23, 2016.

From Our Partners
Tags: AnthraxASPRBARDABioterrorismHHSRFIVaccines

Related Posts

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps
Outbreak News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies
Biosurveillance

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC